Application of psoromic acid in preparation of medicine for treating brain glioma and acute myeloid leukemia

A technology for glioma, acute myeloid, applied in the field of medicine

Inactive Publication Date: 2016-07-20
SUZHOU GENHOUSE PHARMA RES & DEV CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no report about the therapeutic effect of tea carcharic acid on glioma and acute myeloid leukemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of psoromic acid in preparation of medicine for treating brain glioma and acute myeloid leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Inhibition of the growth of U87MG cells by tea scacharic acid:

[0020] Take U87MG cells in the logarithmic growth phase, digest with 2.5% trypsin, count, and the cell concentration is 2×10 4 100 μL was inoculated in a 96-well plate. After culturing for 24 hours to allow them to adhere to the wall, U87MG cells were treated with different concentrations of tea carcharic acid (30 μM, 10 μM, 3 μM, 1 μM, 0.3 μM, 0.1 μM,) for 48 hours, MTT 20 μL / well was added, incubated at 37 ° C for 4 hours, discarded For the supernatant, add 150 μl of DMSO to each well to dissolve the formazan particles, and shake slightly to dissolve. Optical density (OD) was measured at a wavelength of 570 nm. The light absorbance value of the measured well / the light absorbance value of the control well was used as the numerical value of the cell viability. According to the cell viability, calculate the IC of tea carcharic acid on U87MG cells 50 value.

[0021] Results: IC of tea carcharic acid on ...

Embodiment 2

[0023] Inhibition of the growth of TF-1 cells by tea scacharic acid:

[0024] Take TF-1 cells in the logarithmic growth phase, digest with 2.5% trypsin, count, and the cell concentration is 2×10 5 100 μL was inoculated in a 96-well plate. After culturing for 24 hours to allow them to adhere to the wall, TF-1 cells were treated with different concentrations of tea carcharic acid (300 μM, 100 μM, 30 μM, 10 μM, 3 μM, 1 μM,) for 48 hours, and MTT 20 μL / well was added, incubated at 37 ° C for 4 hours, and then discarded. For the supernatant, add 150 μl of DMSO to each well to dissolve the formazan particles, and shake slightly to dissolve. Optical density (OD) was measured at a wavelength of 570 nm. The light absorbance value of the measured well / the light absorbance value of the control well was used as the numerical value of the cell viability. According to the cell viability, calculate the IC of tea carcharic acid on TF-1 cells 50 value.

[0025] Results: IC of tea carchari...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of psoromic acid in the preparation of medicine for treating brain glioma and acute myeloid leukemia. The psoromic acid plays an obvious role in inhibiting the growth of a human brain glioma cell line U87MG and a human erythroid leukemia cell line TF-1. The psoromic acid belongs to natural products and has the characteristics of low toxic or side effects and high bioavailability when the psoromic acid is used for treating brain glioma and acute myeloid leukemia, thereby having certain clinical use value.

Description

technical field [0001] The invention relates to the application of tea scaba acid in the preparation of medicines for treating glioma and acute myeloid leukemia, and belongs to the technical field of medicine. Background technique [0002] Glioma is currently the most common primary malignant tumor of the nervous system. It has the characteristics of rapid invasion, short survival period, and easy recurrence after surgery. At present, the use of advanced technologies such as navigation and minimally invasive surgery in traditional treatment methods and various new radiotherapy and chemotherapy regimens after surgery have failed to reduce the high morbidity and mortality of gliomas. Complications, side effects and high risks also reduce the treatment effect and quality of life. People are eager to seek more effective, safer and faster treatment methods to fight against glioma. Therefore, it is of great significance to develop and research effective drugs for the treatment of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P35/00A61P35/02
CPCA61K31/365
Inventor 姬飞虹王晓峰
Owner SUZHOU GENHOUSE PHARMA RES & DEV CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap